Imatinib mesylate in combination with docetaxel for the treatment of patients with advanced, platinum‐resistant ovarian cancer and primary peritoneal carcinomatosis
Daniela Matei(Northwestern University), Gregory P. Sutton(University of Lincoln)
Cited by 75
Related Papers
Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial
|The Lancet Oncology|2019|533
NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019
|Journal of the National Comprehensive Cancer Network|2019|332
EZH2 inhibition promotes epithelial-to-mesenchymal transition in ovarian cancer cells
|Oncotarget|2016|90
A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer
|Clinical Cancer Research|2019|90
Ovarian Cancer—Why Lipids Matter
|Cancers|2019|80